IRCT20240217061031N1招募中3 期
Preliminary Validation and Determination of the Effectiveness of Acceptance Based Emotion Regulation Group Intervention on the Severity of Signs and Symptoms, Emotional Dysregulation and Quality of Life in Type 1 Bipolar Patients
Artesh University of Medical Sciences0 个研究点目标入组 36 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Definitive Diagnosis of Type 1 Bipolar Disorder by Psychiatric Colleagues
- •Absence of Psychotic Disorders, Substance Abuse Based on Structured Clinical Interview for Disorders 5DSM-Clinical Version (CV-5-SCID)
- •Absence of Severe Personality Disorders According to Milon's Theory Based on Structured Clinical Interview for 5DSM Disorders Personality Disorder Version (PD-5-SCID)
- •Minimum Education is Diploma
- •Knowledge of Research Objectives and Consent to Participate in Research
排除标准
- •Suicidal Thoughts and Attempts While Attending Meetings
- •Participation in Psychotherapy Intervention While Attending the Research
- •Absence in More than 3 Treatment Sessions
研究者
相似试验
招募中
2 期
Development, Validation and Evaluation of the Effectiveness of the native Spiritual Care Protocol Based on Iranian-Islamic Culture in Advance Cancer Patients and Their Caregiversadvance cancer.Malignant neoplasm without specification of siteIRCT20220509054792N1Iran University of Medical Sciences5
已完成
1 期
An Open-Label, Phase 1 Study to Characterize the Effects of a Moderate CYP3A4 and P-glycoprotein Inhibitor on the Pharmacokinetics of Bomedemstat (IMG-7289) in Healthy ParticipantsCancer - MyelomaBlood - Haematological diseasesCancerACTRN12623001006639Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc.24
已完成
2 期
An Open Label, Phase 1/2a Trial to Evaluate the Efficacy, Safety, and Tolerability of KU002 Given as Intravesical Instillations in Subjects with Interstitial Cystitis (IC)/Bladder Pain Syndrome (BPS)*NL-OMON52788Kuste Biopharma14
进行中（未招募）
1 期
The purpose of the research study is to determine if domatinostat in combination with avelumab will be able to delay or prevent worsening of the disease in patients with advanced unresectable/metastatic Merkel Cell Carcinoma that is continuing to grow after previous anti-PD-(L)1 antibody therapy. Furthermore, safety of the combination during the study conduct will be assessed.patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD(L)1 antibody therapyMedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000004864EUCTR2018-004788-30-FR4SC AG40
进行中（未招募）
1 期
The purpose of the research study is to determine if domatinostat in combination with avelumab will be able to delay or prevent worsening of the disease in patients with advanced unresectable/metastatic Merkel Cell Carcinoma that is continuing to grow after previous anti-PD-(L)1 antibody therapy. Furthermore, safety of the combination during the study conduct will be assessed.EUCTR2018-004788-30-NL4SC AG40